Lineage Cell Therapeutics Inc

ASE:LCTX  
2.25
+0.08 (+3.69%)
Products, Regulatory

Lineage Cell Provides Update On OPC1 Cell Therapy Program For Treatment Of Spinal Cord Injury

Published: 12/08/2020 13:29 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage Cell Therapeutics Inc - Provides Update on Opc1 Cell Therapy Program for Treatment of Spinal Cord Injury.
Lineage Cell Therapeutics Inc - Major Improvements Made to Opc1 Production, Including to Process, Purity, Potency, and Scale.
Lineage Cell Therapeutics - Filing of Patent Applications on Process, Product Which, If Allowed, Anticipated to Have Expiration Dates in 2039 and 2040.